Predominance of RAD21 and ERBB2 amplification and progesterone receptor positivity in tumors of the right breast support breast cancer lateralization.

e12557 Background: Biologic lateralization broadly impacts breast cancer. Malignancies originating in the left breast compared to the right breast tend to be more frequent, larger and of poorer prognosis. Left breast tumors respond differently to HER2-neu signaling and have lateralized Ki67 expression. In a prior study a right-left asymmetry in the neutrophil/lymphocyte ratio (NLR) of breast cancers was identified (ASCO 2018, e13094). As a follow-up, retrospective analysis of results from comprehensive genomic profiling (CGP) of right and left side breast cancer specimens was performed to determine a potential genomic etiology for the observed NLR lateralization. Methods: Tumors from 43 consecutive breast cancer patients underwent analysis for all classes of genomic alterations by hybrid capture-based CGP (Foundation Medicine). The CGP results from the 25 left- and 18 right-sided breast cancer samples were analyzed along with the histologic grade and status of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. Results: In this cohort of advanced breast cancer patients (stage 3-4), no statistically significant differences in lateralization were identified based on patient age, tumor stage, or frequency of ER or Her2 expression (Table). A predominance of PR positivity (p=0.14 chi square analysis) and amplifications in the ERBB2 (p=0.37) and RAD21 (p=0.08) genes were detected in right side tumors. Conclusions: Together with the prior study, trends in asymmetry based on genomic, pathologic, and immunohistologic differences have been detected in breast cancers, including an increased incidence of ERBB2 and RAD21 amplification in right-side breast tumors in this cohort. The predominance of lower PR positivity in the left breast tumors may be due to preferential hypermethylation, consistent with reports that it mediates biologic lateralization changes, downregulates PR expression, and alters amplification rates. Epigenetic methylation, may contribute to asymmetric breast cancer biology and have implications for therapeutic strategy. Further study is warranted.[Table: see text]

Download Full-text

The Frequency of Low HER2 Expression in Breast Cancer and A Comparison of Prognosis Between Patients With HER2-Low and HER2-Negative Breast Cancer By HR Status

10.21203/rs.3.rs-298935/v1 ◽

2021 ◽

Author(s):

Nanae Horisawa ◽

Yayoi Adachi ◽

Daiki Takatsuka ◽

Kazuki Nozawa ◽

Yuka Endo ◽

...

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Treatment Strategies ◽

Biological Data ◽

Breast Cancers ◽

Her2 Expression ◽

Breast Cancer Patients ◽

Her2 Amplification ◽

Her2 Positive ◽

Positive Breast Cancer

Abstract PurposeThe DESTINY-Breast04 clinical trial is currently investigating whether trastuzumab deruxtecan (T-DXd) is effective in HER2-low as well as HER2-positive breast cancer. This highlights the interest in treatment strategies for patients with HER2-low breast cancer. The current study was therefore designed to determine the frequency of HER2-low among all breast cancers, and to compare the prognosis of HER2-low patients with that of HER2-negative patients. MethodsWe retrospectively reviewed the biological data from 4,918 of 4,977 primary breast cancer patients who attended our institute. We quantified the overall frequency of breast cancer patients with a new HER2-low subtype that was defined by an immunohistochemistry score of IHC1+ or IHC2+/ISH-. We then compared the clinical characteristics and prognosis of HER2-low patients with that of patients who did not have HER2 amplification (HER2-0). ResultsLow HER2 expression was found in 3169 (64.4%) patients; 2860 (58.1%) were HR-positive and 309(6.3%) were HR-negative. Among HER2-0 patients, 681(13.9%) were HR-positive and 157(3.2%) were HR-negative. The HER2-0 group tended to have more poor prognostic factors than the HER2-low group, irrespective of HR status. There were no statistically significant differences between the prognosis of HER2-low and HER2-0 patients, regardless of HR status. However, patients in the HER2-low group tended to have better prognosis than those in the HER2-0 group.ConclusionHER2-low patients did not have a significantly different prognosis than HER2-0 patients, regardless of HR status. However, we should consider tailoring therapies for patients with HRE2-low early breast cancer according to their HR status.

Download Full-text

Molecular Subtypes of Breast Cancer Patients According to St Gallen Classification

Chattagram Maa-O-Shishu Hospital Medical College Journal ◽

10.3329/cmoshmcj.v19i1.48805 ◽

2020 ◽

Vol 19 (1) ◽

pp. 55-58

Author(s):

Shafatujjahan ◽

Ifatujjahan ◽

Rajat Sanker Roy Biswas

Keyword(s):

Breast Cancer ◽

Cancer Patients ◽

Molecular Subtypes ◽

Hormonal Treatment ◽

Left Breast ◽

Breast Cancers ◽

Breast Cancer Patients ◽

Luminal A ◽

Luminal B ◽

Her 2

Introduction: Breast cancer is a common malignancy among female in Bangladesh.But its molecular subtypes are not evaluated due to lack of expert investigationsupport. So objectives of the present study are to evaluate the molecular subtypesof breast cancer patients according to St Gallen classification in our contest. Materials and methods: It is retrospective study done among histopathologicallyproved 40 breast cancer patients visiting Medical Oncology and Radiotherapydepartment of Chattogram Maa-O-Shishu Hospital. Molecular subtypes wasevaluated by immunohistochemistry according to St Gallen Classification. Results: In this study a total of 40 cases of invasive female breast cancers wereincluded. Age of the patients ranged from 31-62 years, with a mean age of 41 ±13.5 years. ER expression was seen in 60% and PR in 55% of cases and Her-2/neupositivity in 16%. Majority (52.5%) of the tumors were located in the left breast. Thepercentage of ER but not PR positivity increased with age, though this differencewas not statistically significant. Majority of the cases were diagnosed at stage IIwith a percentage of 42.5%. Stage II tumors showed more ER and PR positivity.Among all 57.9% of ER positive and 49.5% of PR positive tumors were present while72.2% of tumors were negative for Her-2/neu. The triple-negative breast tumorswere more commonly found at grade 2. Regarding luminal status 14(35%) wasLuminal A, 5(12.5%) was Luminal B, 9(22.5%) was TNBC and 12(30%) was HER 2positive. Conclusion: In this study luminal A was the commonest molecular subtypes. LuminalA subtypes tumors had a long term risk of distant matastatic disease which can bereduced by hormonal treatment. Chatt Maa Shi Hosp Med Coll J; Vol.19 (1); January 2020; Page 55-58

Download Full-text

Is There a Bias Against Obese Patients in the Treatment of Breast Cancer?

The American Surgeon ◽

10.1177/0003134820984877 ◽

2020 ◽

pp. 000313482098487

Author(s):

Melinda Wang ◽

Julian Huang ◽

Anees B. Chagpar

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Cancer Patients ◽

Prophylactic Mastectomy ◽

Implicit Bias ◽

Treatment Decision ◽

Obese Patients ◽

Breast Cancers ◽

Breast Cancer Patients ◽

Immediate Reconstruction

Background Patient and tumor characteristics often coincide with obesity, potentially affecting treatment decision-making in obese breast cancer patients. Independent of all of these factors, however, it is unclear whether obesity itself impacts the decision to offer patients undergoing mastectomy breast reconstruction, postmastectomy radiation therapy (PMRT), or neoadjuvant chemotherapy. We sought to determine whether implicit bias against obese breast cancer patients undergoing mastectomy plays a role in their treatment. Methods Medical records of breast cancer patients undergoing mastectomy from January 2010 to April 2018 from a single institution were retrospectively reviewed, separated into obese (BMI ≥30) and nonobese (BMI <30) categories, and compared using nonparametric statistical analyses. Results Of 972 patients, 291 (31.2%) were obese. Obese patients were more likely to have node-positive, triple-negative breast cancers ( P = .026) and were also more likely to have other comorbidities such as a history of smoking ( P = .026), hypertension ( P < .001), and diabetes ( P < .001). Receipt of immediate reconstruction and contralateral prophylactic mastectomy did not vary between obese and nonobese patients. While obese patients were more likely to undergo neoadjuvant chemotherapy (26.5% vs. 18.1%, P = .004) and PMRT (33.0% vs. 23.4%, P = .003), this did not remain significant when controlling for comorbidities and clinicopathologic confounders. Conclusion Obese patients present with more aggressive tumors and often have concomitant comorbidities. Independent of these factors, however, differences in the treatment of patients undergoing mastectomy do not seem to be affected by an implicit bias against obese patients.

Download Full-text

Tracing Human Papilloma Virus in Breast Tumors of Iranian Breast Cancer Patients

The Breast Journal ◽

10.1111/j.1524-4741.2010.01053.x ◽

2011 ◽

Vol 17 (2) ◽

pp. 218-219 ◽

Cited By ~ 3

Author(s):

Saeed Reza Ghaffari ◽

Tayebeh Sabokbar ◽

Zahra Meshkat ◽

Forouzandeh Fereidooni ◽

Jila Dastan ◽

...

Keyword(s):

Breast Cancer ◽

Human Papilloma Virus ◽

Cancer Patients ◽

Breast Tumors ◽

Breast Cancer Patients ◽

Papilloma Virus

Download Full-text

Survival Benefit of Tamoxifen in Estrogen Receptor-Negative and Progesterone Receptor-Positive Low Grade Breast Cancer Patients

Journal of Breast Cancer ◽

10.4048/jbc.2012.15.3.288 ◽

2012 ◽

Vol 15 (3) ◽

pp. 288 ◽

Cited By ~ 26

Author(s):

Li-Heng Yang ◽

Hsin-Shun Tseng ◽

Che Lin ◽

Li-Sheng Chen ◽

Shou-Tung Chen ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Progesterone Receptor ◽

Cancer Patients ◽

Survival Benefit ◽

Low Grade ◽

Breast Cancer Patients ◽

Estrogen Receptor Negative

Download Full-text

A Clinicopathological Study of Pre and Post Menopausal Breast Cancer Patients in North Bengal Population & Their Correlation with Estrogen and Progesterone Receptor Status

Journal of Medical Science And clinical Research ◽

10.18535/jmscr/v7i11.156 ◽

2019 ◽

Vol 7 (11) ◽

Author(s):

Dr Suparna Banerjee ◽

Keyword(s):

Breast Cancer ◽

Progesterone Receptor ◽

Cancer Patients ◽

Progesterone Receptor Status ◽

Breast Cancer Patients ◽

Receptor Status ◽

Clinicopathological Study ◽

Post Menopausal ◽

Estrogen And Progesterone Receptor ◽

North Bengal

Download Full-text

Regression of Triple-Negative Breast Cancer in a Patient-Derived Xenograft Mouse Model by Monoclonal Antibodies against IL-12 p40 Monomer

Cells ◽

10.3390/cells11020259 ◽

2022 ◽

Vol 11 (2) ◽

pp. 259

Author(s):

Madhuchhanda Kundu ◽

Sumita Raha ◽

Avik Roy ◽

Kalipada Pahan

Keyword(s):

Breast Cancer ◽

Mouse Model ◽

Cancer Patients ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Transforming Growth Factor ◽

Healthy Controls ◽

Breast Cancers ◽

Breast Cancer Patients ◽

Patient Derived Xenograft

Although some therapies are available for regular breast cancers, there are very few options for triple-negative breast cancer (TNBC). Here, we demonstrated that serum level of IL-12p40 monomer (p40) was much higher in breast cancer patients than healthy controls. On the other hand, levels of IL-12, IL-23 and p40 homodimer (p402) were lower in serum of breast cancer patients as compared to healthy controls. Similarly, human TNBC cells produced greater level of p40 than p402. The level of p40 was also larger than p402 in serum of a patient-derived xenograft (PDX) mouse model. Accordingly, neutralization of p40 by p40 mAb induced death of human TNBC cells and tumor shrinkage in PDX mice. While investigating the mechanism, we found that neutralization of p40 led to upregulation of human CD4+IFNγ+ and CD8+IFNγ+ T cell populations, thereby increasing the level of human IFNγ and decreasing the level of human IL-10 in PDX mice. Finally, we demonstrated the infiltration of human cytotoxic T cells, switching of tumor-associated macrophage M2 (TAM2) to TAM1 and suppression of transforming growth factor β (TGFβ) in tumor tissues of p40 mAb-treated PDX mice. Our studies identify a possible new immunotherapy for TNBC in which p40 mAb inhibits tumor growth in PDX mice.

Download Full-text

Immunotherapy and prevention of breast cancer

Muthanna Medical Journal ◽

10.52113/1/7.2/2020.70 ◽

2020 ◽

Vol 7 (2) ◽

pp. 58-70

Author(s):

Neelam Thacker ◽

Perianayagam Taneja

Keyword(s):

Breast Cancer ◽

Monoclonal Antibodies ◽

Cancer Patients ◽

Triple Negative ◽

Standard Of Care ◽

Breast Tumors ◽

Cancer Death ◽

Breast Cancer Patients ◽

Conventional Chemotherapy ◽

Prevention Of Breast Cancer

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of cancer death in women worldwide. Despite the significant benefit of the use of conventional chemotherapy and monoclonal antibodies in the prognosis of breast cancer patients and although the recent approval of the anti-PD-L1 antibody atezolizumab in combination with chemotherapy has been a milestone for the treatment of patients with metastatic triple-negative breast cancer, immunologic treatment of breast tumors remains a great challenge. In this review, we summarize current breast cancer classification and standard of care, the main obstacles that hinder the success of immunotherapies in breast cancer patients, as well as different approaches that could be useful to enhance the response of breast tumors to immunotherapies.

Download Full-text